COMMUNIQUÉS West-GlobeNewswire

Form 8 (DD) - Flemming Ornskov
01/11/2018
FORM 8 (DD) PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS) Rules 8.1, 8.2 and 8.4 of the Takeover Code (the “Code”) [...]
Novo Nordisk's operating profit decreased by 6% in Danish kroner and increased by 2% in local currencies in the first nine months of 2018
01/11/2018
Adjusting for severance costs related to lay-offs in the third quarter of 2018, operating profit increased by 4% in local currencies. Sales decreased by 2% in Danish kroner and increased by 4% in local currencies to DKK [...]
Sanofi and Denali Therapeutics to develop treatments for neurological and inflammatory diseases
01/11/2018
Sanofi and Denali Therapeutics to develop treatments for neurological and inflammatory diseases Candidate molecules have the potential to treat multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), Alzheimer's [...]
Sanofi et Denali Therapeutics vont développer des médicaments pour le traitement de maladies neurologiques et inflammatoires
01/11/2018
Sanofi et Denali Therapeutics vont développer des médicaments pour le traitement de maladies neurologiques et inflammatoires Des molécules candidates pour le traitement potentiel de la sclérose en plaques (SEP), de la [...]
Biocartis Group NV: Eight Idylla(TM) Performance Studies to be Presented at the Association for Molecular Pathology Conference in the US
01/11/2018
PRESS RELEASE : 1 November 2018, 07:00 CEST/00:00 CDT Eight Idylla(TM) Performance Studies to be Presented at the 'Association for Molecular Pathology' Conference in the US Mechelen, Belgium, 1 November 2018 - Biocartis [...]
Denali Therapeutics Announces Broad Collaboration with Sanofi to Develop RIPK1 Inhibitors for the Treatment of Neurological and Inflammatory Diseases
01/11/2018
Candidate RIPK1 inhibitor molecules have the potential to treat Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and systemic inflammatory diseases Denali to receive $125 million [...]
Oasmia completes a private placement of new convertible instruments in the amount SEK 80 million
01/11/2018
Oasmia Pharmaceutical AB (publ) (“Oasmia” or the “Company”) hereby announces that the Company has completed a private placement of a convertible loan in the total amount of SEK 80,000,000 with an interest rate of 5 per [...]
REVA Announces Commercial Launch of the Fantom Encore Bioresorbable Scaffold
01/11/2018
First Fantom Encore Implanted in the FANTOM Post Market Trial SAN DIEGO, Oct. 31, 2018 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for [...]
Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ)
31/10/2018
Oasmia Pharmaceutical AB (publ) (”Oasmia” or ”Company” or “Group”) on 29 November 2017, on 18 April 2018 and on 7 September 2018, issued convertible loans with total nominal amount of MSEK 28, MSEK 26 and MSEK 35.2 [...]
Canada House Wellness Group Inc. Announces Results of Annual General Meeting and Issuance of Stock Options
31/10/2018
TORONTO, Oct. 31, 2018 (GLOBE NEWSWIRE) -- Canada House Wellness Group Inc. (“Canada House” or the “Company”) (CSE: CHV) is pleased to announce the results of the company’s Annual General and Special Meeting of [...]
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
31/10/2018
CAMBRIDGE, Mass., Oct. 31, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, granted equity awards on October 31, 2018, that were previously [...]
IHMA Announces a New Venture in India to Further Their Global Support of Anti-infective Drug Development for the Biopharmaceutical Industry
31/10/2018
SCHAUMBURG, Ill., Oct. 31, 2018 (GLOBE NEWSWIRE) -- International Health Management Associates, Inc./IHMA Europe Sàrl (IHMA), a global company that provides laboratory and consultative services to the biopharmaceutical [...]
UPDATE - Melinta Therapeutics Announces Appointment of Bruce L. Downey to Board of Directors
31/10/2018
NEW HAVEN, Conn., Oct. 31, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial [...]
LHC Group Announces Third Quarter 2018 Financial Results
31/10/2018
Affirms Guidance and Expectations for 12% to 15% Adjusted Earnings Accretion from Almost Family Acquisition in 2018 LAFAYETTE, La., Oct. 31, 2018 (GLOBE NEWSWIRE) -- LHC Group, Inc. (NASDAQ: LHCG) announced its [...]
Galapagos reports initiation of PINTA Phase 2 trial with GLPG1205 in patients with Idiopathic Pulmonary Fibrosis (IPF)
31/10/2018
Mechelen, Belgium; 31 October 2018; 22:01 CET - Galapagos NV (Euronext & NASDAQ: GLPG) reports first dosing in the PINTA Phase 2 trial with its GPR84 antagonist GLPG1205 in patients with idiopathic pulmonary [...]
Forty Seven Inc. Announces Publication in The New England Journal of Medicine of 5F9 Phase 1b Clinical Data in Non-Hodgkin’s Lymphoma (NHL)
31/10/2018
Publication Reaffirms Therapeutic Potential of CD47 Inhibition as Novel Approach to Treating Cancer Enrollment Ongoing in Phase 2 Portion of Clinical Trial Evaluating 5F9 in Combination with Rituximab for Patients with [...]
PRA Health Sciences, Inc. Reports Third Quarter 2018 Results and Updates 2018 Guidance
31/10/2018
Net new business of $657.2 million; Net book-to-bill of 1.28 $717.6 million of revenue; 23.3% growth at actual foreign exchange rates and 24.0% growth on a constant currency basis $572.9 million of revenue excluding the [...]
With Recent Acquisitions, NewBridge Global Ventures Creates Impressive Offering - CFN Media
31/10/2018
Seattle, WA, Oct. 31, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication [...]
Reata Pharmaceuticals, Inc. to Report Third Quarter 2018 Financial Results and Provide an Update on Development Programs on Wednesday, November 7, 2018
31/10/2018
IRVING, Texas, Oct. 31, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that the company will report third quarter 2018 financial results [...]

Pages